PhosPrint P.C. develops a laser bioprinting system that precisely delivers viable cells and bioinks for tissue regeneration and biosensor applications. This technology provides a novel method for treating bladder cancer, offering a safer alternative to existing treatment options.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current bladder cancer treatments have limitations and potential side effects. Existing methods for tissue regeneration and creating biosensors lack precision and speed in cell and bio-ink delivery.
Solution
PhosPrint P.C. develops laser bioprinting technology for precise and rapid delivery of viable cells and bio-inks onto substrates, targeting tissue regeneration and biosensor applications. Their PhosDB I system is a high-resolution, user-friendly laser bioprinter designed for demanding cell-printing applications. The company's innovative in vivo laser bioprinting system is designed for regenerative medicine applications in urology, offering a novel alternative method to current treatment options for bladder cancer patients. The bioprinted neobladder method is safe and eliminates side effects, offering an innovative solution to improve patients' quality of life.
Target Audience
The primary target audience includes medical professionals in urology, researchers in regenerative medicine, and organizations involved in biosensor development.
Features
- High-resolution laser bioprinting for precise cell and bio-ink placement
- Rapid delivery of cells and bio-inks
- PhosDB I system designed for demanding cell-printing applications
- In vivo bioprinting capabilities for direct tissue regeneration
- Technology applicable to both tissue regeneration and biosensor creation